Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Knowledge Hub

Implementing pneumonia vaccination programs can significantly reduce hospitalizations

Assuming 90% coverage, a program in The Gambia using a 9-valent PCV (PCV9) would prevent approximately 630 hospitalizations, 40 deaths, and 1000 DALYs over the first 5 years of life of a birth cohort. The estimated cost would be $670 per DALY averted in The Gambia.

Full Citation:
Kim, S., Lee, G. and Goldie, S.. 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infectious Diseases. 10(260).

Title of Article: Economic evaluation of pneumococcal conjugate vaccination in The Gambia

Author(s): Kim, S., Lee, G. and Goldie, S.

Publication Year: 2010

Publication Name: BMC Infectious Diseases

Publication Volume: 10(260)

Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944347/

DOI (Digital Object Identifier): 10.1186/1471-2334-10-260

Topics: Economics & Return on Investment

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: Gambia

WHO Regions: Africa